MicroPort CardioFlow Medtech Corporation provided earnings guidance for the six months ended June 30, 2022. For the six months, the company expected to record a revenue of no less than RMB 120 million for the six months ended June 30, 2022, representing an increase of over 40% as compared to that of the same period last year. The increase in revenue of the Group is mainly attributable to the Group's continued commercialization of VitaFlow® and VitaFlow LibertyTM and the increasing number of implantations.

As of June 30, 2022, there are more than 370 hospitals in China using VitaFlow® and VitaFlow LibertyTM, most of which are class IIIA hospitals located at tier-one and tier-two cities. Also, Net loss is expected to be approximately RMB 120 million to RMB 135 million for the six months ended June 30, 2022, compared to approximately RMB 70 million for the six months ended June 30, 2021. The expected increase in the net loss of the Group is mainly attributable to the company's continued investment in research and development and further commercialization efforts.